Canadian Patent Secured for Klotho Gene Therapy Targeting Alzheimer's, ALS
GRML sits 22% above its 52-week low of $0.156 on light trading volume (0.3× avg).
Summary
Greenland Mines received a Canadian patent for its Klotho gene therapy technology, covering 42 claims for treating neurodegenerative diseases like Alzheimer's and ALS. This expands its IP portfolio beyond existing U.S., China, and Europe patents. The company also disclosed that lead candidate KLTO-101 will begin process development in August 2026, while KLTO-202 has advanced to GMP manufacturing ahead of planned regulatory interactions later this year. For a micro-cap company with a market cap around $29 million and ongoing financial distress, this biotech progress represents a material step toward potential value creation, though significant funding and clinical hurdles remain.
At the time of this announcement, GRML was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.1M. The 52-week trading range was $0.16 to $1.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.